Skip to content
Friday, 30 October 2026
BREAKING
BUSINESS

Dr Reddy’s Laboratories trades higher on the BSE

Mumbai, October 30 (Udaipur Kiran): Dr. Reddy’s Laboratories is currently trading at Rs. 1359.05, up by 20.55 points or 1.54% from its previous closing of Rs. 1338.50 on the BSE.

The scrip opened at Rs. 1346.45 and has touched a high and low of Rs. 1363.45 and Rs. 1345.30 respectively. So far 141164 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 1414.40 on 29-Jun-2026 and a 52 week low of Rs. 1080.05 on 23-Jul-2026.

Last one week high and low of the scrip stood at Rs. 1,363.45 and Rs. 1,225.20 respectively. The current market cap of the company is Rs. 113453.92 crore.

The promoters holding in the company stood at 26.63%, while Institutions and Non-Institutions held 52.18% and 10.08% respectively.

The United States Food & Drug Administration (USFDA) has classified the inspection outcome of Dr Reddy’s Laboratories’ FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, as ‘Voluntary Action Indicated’ (VAI) and officially closed the inspection. The USFDA had conducted Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at the company’s said unit in Andhra Pradesh.

According to the US health regulator’s guidelines, a VAI classification means that objectionable conditions or practices were observed during the inspection, but the agency is not recommending or taking any regulatory or administrative action.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.